These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33964158)

  • 1. Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule.
    Hoes J; King AJ; Klooster TMSV; Berkhof J; Bogaards JA; de Melker HE
    J Infect Dis; 2022 Sep; 226(4):634-643. PubMed ID: 33964158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
    Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
    J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
    Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
    J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of bivalent HPV vaccination against genital HPV DNA-positivity of a catch-up campaign at age 13-16 years compared to routine vaccination at age 12 years: a biennial repeated cross-sectional study.
    Kusters JMA; van der Loeff MFS; van Benthem BHB; King AJ; ; de Melker HE; Heijman T; Heijne JCM
    BMC Med; 2024 Oct; 22(1):469. PubMed ID: 39407233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.
    Tsang SH; Sampson JN; Schussler J; Porras C; Wagner S; Boland J; Cortes B; Lowy DR; Schiller JT; Schiffman M; Kemp TJ; Rodriguez AC; Quint W; Gail MH; Pinto LA; Gonzalez P; Hildesheim A; Kreimer AR; Herrero R;
    J Natl Cancer Inst; 2020 Oct; 112(10):1030-1037. PubMed ID: 32091596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
    Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
    J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.
    Hoes J; Woestenberg PJ; Bogaards JA; King AJ; de Melker HE; Berkhof J; Hoebe CJPA; van der Sande MAB; van Benthem BHB;
    Clin Infect Dis; 2021 Mar; 72(5):e103-e111. PubMed ID: 33249475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women.
    van Eer K; Middeldorp M; Dzebisasjvili T; Lamkaraf N; de Melker HE; Steenbergen RDM; King AJ
    J Infect Dis; 2023 Oct; 228(8):1012-1022. PubMed ID: 36988110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
    Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
    Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine Trial.
    Befano B; Campos NG; Egemen D; Herrero R; Schiffman M; Porras C; Lowy DR; Rodriguez AC; Schiller JT; Ocampo R; Hildesheim A; Sampson JN; Das S; Kreimer AR; Cheung LC;
    J Natl Cancer Inst; 2023 Jul; 115(7):788-795. PubMed ID: 37040086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands.
    Woestenberg PJ; King AJ; Van Benthem BHB; Leussink S; Van der Sande MAB; Hoebe CJPA; Bogaards JA;
    J Infect Dis; 2020 Mar; 221(8):1280-1285. PubMed ID: 31100134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
    Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
    Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study.
    Mollers M; King AJ; Knol MJ; Scherpenisse M; Meijer CJ; van der Klis FR; de Melker HE
    Vaccine; 2015 May; 33(23):2678-83. PubMed ID: 25887090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
    Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females.
    van der Weele P; Breeuwsma M; Donken R; van Logchem E; van Marm-Wattimena N; de Melker H; Meijer CJLM; King AJ
    PLoS One; 2019; 14(3):e0212927. PubMed ID: 30830913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
    Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
    Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
    Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.